Ireland-based drugmaker Horizon Pharma (Nasdaq: HZNP) saw its share price drop by more than 5% in a day following news that it will pay US pharmacy benefit manager Express Scripts $65 million to settle rebate litigation.
Express Scripts had initially asked for $166.2 million as it took legal action in November of last year against the Dublin-based company for alleged after-market rebates for three of its medicines.
These were Rayos (prednisone), a rheumatology treatment, along with pain relief products Duexis (ibuprofen/famotidine) and Vimovo (naproxen/esomeprazole magnesium).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze